Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Brokerages

Agenus Inc. (NASDAQ:AGEN) has been assigned a consensus rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.75.

A number of equities research analysts have commented on AGEN shares. Robert W. Baird cut their target price on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a report on Tuesday, March 18th. Finally, StockNews.com raised Agenus from a “sell” rating to a “hold” rating in a report on Friday, March 21st.

Agenus Price Performance

Agenus stock opened at $1.67 on Wednesday. Agenus has a one year low of $1.55 and a one year high of $19.69. The business’s fifty day moving average is $2.95 and its 200 day moving average is $3.61. The stock has a market capitalization of $42.27 million, a PE ratio of -0.15 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. As a group, sell-side analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

Several institutional investors and hedge funds have recently bought and sold shares of AGEN. EP Wealth Advisors LLC bought a new position in shares of Agenus in the third quarter worth about $55,000. Corton Capital Inc. purchased a new stake in Agenus in the 4th quarter worth approximately $36,000. Point72 DIFC Ltd raised its stake in Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 11,542 shares during the period. Virtu Financial LLC purchased a new position in Agenus during the fourth quarter valued at approximately $51,000. Finally, Apollon Wealth Management LLC bought a new position in shares of Agenus in the fourth quarter worth approximately $55,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.